Abstract
Objective: To evaluate the analgesic effects of orally administered gabapentin on horses with chronic thoracic limb lameness. Study design: Randomized, crossover design. Animals: A total of 14 adult horses with chronic thoracic limb lameness. Methods: Following baseline measurement of lameness, horses were administered each of four treatments orally in grain: treatment G, gabapentin (20 mg kg–1) twice daily for 13 doses; treatment F, firocoxib (171 mg once, then 57 mg once daily for six doses); treatment GF, gabapentin and firocoxib at previously stated doses and frequencies; or treatment C, grain only as a control. Treatments were administered in a randomized, crossover design, separated by 2 weeks. Subjective lameness score (SLS), inertial sensor vector sum (VS) calculations, peak vertical ground reaction force (PVGRF) measurements and vertical impulse (VI) calculations were determined immediately prior to each initial treatment dose and 2–4 hours after the final treatment dose for each treatment. Mean change in SLS, VS, PVGRF and VI for each treatment were compared among treatments. Results: The rank change in SLS of treatment GF was significantly greater than that of treatments C (p = 0.01) and G (p = 0.01) but not of treatment F (p = 0.08). No differences in VS (p = 0.4), PVGRF (p = 0.4) or VI (p = 0.1) were observed among treatments. Conclusions and clinical relevance: Gabapentin, as administered here, did not improve subjective or objective measures of lameness in horses with chronic thoracic limb musculoskeletal pain. Although subjective evaluation identified an improvement in lameness with treatment GF, it was not different from that observed with treatment F. Higher oral dosing and longer treatment regimens of gabapentin may be indicated for the treatment of chronic musculoskeletal pain in horses.
Original language | English (US) |
---|---|
Pages (from-to) | 259-266 |
Number of pages | 8 |
Journal | Veterinary anaesthesia and analgesia |
Volume | 47 |
Issue number | 2 |
DOIs | |
State | Published - Mar 2020 |
Externally published | Yes |
Bibliographical note
Funding Information:
Funding for this project was provided by the Oklahoma State University, College of Veterinary Medicine, Research Advisory Committee , OK, USA. The firocoxib tablets were provided by Merial Inc., GA, USA.
Funding Information:
Funding for this project was provided by the Oklahoma State University, College of Veterinary Medicine, Research Advisory Committee, OK, USA. The firocoxib tablets were provided by Merial Inc. GA, USA.
Publisher Copyright:
© 2019 Association of Veterinary Anaesthetists and American College of Veterinary Anesthesia and Analgesia
Keywords
- equine chronic lameness
- firocoxib
- gabapentin
- pain management
Publisher link
Find It
Other files and links
Fingerprint
Dive into the research topics of 'Efficacy of orally administered gabapentin in horses with chronic thoracic limb lameness'. Together they form a unique fingerprint.
View full fingerprint
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
Young, J. M., Schoonover, M. J., Kembel, S. L., Taylor, J. D., Bauck, A. G., & Gilliam, L. L. (2020). Efficacy of orally administered gabapentin in horses with chronic thoracic limb lameness. Veterinary anaesthesia and analgesia, 47(2), 259-266. https://doi.org/10.1016/j.vaa.2019.11.003
Efficacy of orally administered gabapentin in horses with chronic thoracic limb lameness. / Young, Jenna M.; Schoonover, Mike J.; Kembel, S. Logan et al.
In: Veterinary anaesthesia and analgesia, Vol. 47, No. 2, 03.2020, p. 259-266.
Research output: Contribution to journal › Article › peer-review
Young, JM, Schoonover, MJ, Kembel, SL, Taylor, JD, Bauck, AG & Gilliam, LL 2020, 'Efficacy of orally administered gabapentin in horses with chronic thoracic limb lameness', Veterinary anaesthesia and analgesia, vol. 47, no. 2, pp. 259-266. https://doi.org/10.1016/j.vaa.2019.11.003
Young JM, Schoonover MJ, Kembel SL, Taylor JD, Bauck AG, Gilliam LL. Efficacy of orally administered gabapentin in horses with chronic thoracic limb lameness. Veterinary anaesthesia and analgesia. 2020 Mar;47(2):259-266. doi: 10.1016/j.vaa.2019.11.003
Young, Jenna M. ; Schoonover, Mike J. ; Kembel, S. Logan et al. / Efficacy of orally administered gabapentin in horses with chronic thoracic limb lameness. In: Veterinary anaesthesia and analgesia. 2020 ; Vol. 47, No. 2. pp. 259-266.
@article{fd9032fb5bbb42c5bfa1a98a3f83521c,
title = "Efficacy of orally administered gabapentin in horses with chronic thoracic limb lameness",
abstract = "Objective: To evaluate the analgesic effects of orally administered gabapentin on horses with chronic thoracic limb lameness. Study design: Randomized, crossover design. Animals: A total of 14 adult horses with chronic thoracic limb lameness. Methods: Following baseline measurement of lameness, horses were administered each of four treatments orally in grain: treatment G, gabapentin (20 mg kg–1) twice daily for 13 doses; treatment F, firocoxib (171 mg once, then 57 mg once daily for six doses); treatment GF, gabapentin and firocoxib at previously stated doses and frequencies; or treatment C, grain only as a control. Treatments were administered in a randomized, crossover design, separated by 2 weeks. Subjective lameness score (SLS), inertial sensor vector sum (VS) calculations, peak vertical ground reaction force (PVGRF) measurements and vertical impulse (VI) calculations were determined immediately prior to each initial treatment dose and 2–4 hours after the final treatment dose for each treatment. Mean change in SLS, VS, PVGRF and VI for each treatment were compared among treatments. Results: The rank change in SLS of treatment GF was significantly greater than that of treatments C (p = 0.01) and G (p = 0.01) but not of treatment F (p = 0.08). No differences in VS (p = 0.4), PVGRF (p = 0.4) or VI (p = 0.1) were observed among treatments. Conclusions and clinical relevance: Gabapentin, as administered here, did not improve subjective or objective measures of lameness in horses with chronic thoracic limb musculoskeletal pain. Although subjective evaluation identified an improvement in lameness with treatment GF, it was not different from that observed with treatment F. Higher oral dosing and longer treatment regimens of gabapentin may be indicated for the treatment of chronic musculoskeletal pain in horses.",
keywords = "equine chronic lameness, firocoxib, gabapentin, pain management",
author = "Young, {Jenna M.} and Schoonover, {Mike J.} and Kembel, {S. Logan} and Taylor, {Jared D.} and Bauck, {Anje G.} and Gilliam, {Lyndi L.}",
note = "Funding Information: Funding for this project was provided by the Oklahoma State University, College of Veterinary Medicine, Research Advisory Committee , OK, USA. The firocoxib tablets were provided by Merial Inc., GA, USA. Funding Information: Funding for this project was provided by the Oklahoma State University, College of Veterinary Medicine, Research Advisory Committee, OK, USA. The firocoxib tablets were provided by Merial Inc. GA, USA. Publisher Copyright: {\textcopyright} 2019 Association of Veterinary Anaesthetists and American College of Veterinary Anesthesia and Analgesia",
year = "2020",
month = mar,
doi = "10.1016/j.vaa.2019.11.003",
language = "English (US)",
volume = "47",
pages = "259--266",
journal = "Veterinary anaesthesia and analgesia",
issn = "1467-2987",
publisher = "Wiley-Blackwell",
number = "2",
}
TY - JOUR
T1 - Efficacy of orally administered gabapentin in horses with chronic thoracic limb lameness
AU - Young, Jenna M.
AU - Schoonover, Mike J.
AU - Kembel, S. Logan
AU - Taylor, Jared D.
AU - Bauck, Anje G.
AU - Gilliam, Lyndi L.
N1 - Funding Information:Funding for this project was provided by the Oklahoma State University, College of Veterinary Medicine, Research Advisory Committee , OK, USA. The firocoxib tablets were provided by Merial Inc., GA, USA. Funding Information:Funding for this project was provided by the Oklahoma State University, College of Veterinary Medicine, Research Advisory Committee, OK, USA. The firocoxib tablets were provided by Merial Inc. GA, USA.Publisher Copyright:© 2019 Association of Veterinary Anaesthetists and American College of Veterinary Anesthesia and Analgesia
PY - 2020/3
Y1 - 2020/3
N2 - Objective: To evaluate the analgesic effects of orally administered gabapentin on horses with chronic thoracic limb lameness. Study design: Randomized, crossover design. Animals: A total of 14 adult horses with chronic thoracic limb lameness. Methods: Following baseline measurement of lameness, horses were administered each of four treatments orally in grain: treatment G, gabapentin (20 mg kg–1) twice daily for 13 doses; treatment F, firocoxib (171 mg once, then 57 mg once daily for six doses); treatment GF, gabapentin and firocoxib at previously stated doses and frequencies; or treatment C, grain only as a control. Treatments were administered in a randomized, crossover design, separated by 2 weeks. Subjective lameness score (SLS), inertial sensor vector sum (VS) calculations, peak vertical ground reaction force (PVGRF) measurements and vertical impulse (VI) calculations were determined immediately prior to each initial treatment dose and 2–4 hours after the final treatment dose for each treatment. Mean change in SLS, VS, PVGRF and VI for each treatment were compared among treatments. Results: The rank change in SLS of treatment GF was significantly greater than that of treatments C (p = 0.01) and G (p = 0.01) but not of treatment F (p = 0.08). No differences in VS (p = 0.4), PVGRF (p = 0.4) or VI (p = 0.1) were observed among treatments. Conclusions and clinical relevance: Gabapentin, as administered here, did not improve subjective or objective measures of lameness in horses with chronic thoracic limb musculoskeletal pain. Although subjective evaluation identified an improvement in lameness with treatment GF, it was not different from that observed with treatment F. Higher oral dosing and longer treatment regimens of gabapentin may be indicated for the treatment of chronic musculoskeletal pain in horses.
AB - Objective: To evaluate the analgesic effects of orally administered gabapentin on horses with chronic thoracic limb lameness. Study design: Randomized, crossover design. Animals: A total of 14 adult horses with chronic thoracic limb lameness. Methods: Following baseline measurement of lameness, horses were administered each of four treatments orally in grain: treatment G, gabapentin (20 mg kg–1) twice daily for 13 doses; treatment F, firocoxib (171 mg once, then 57 mg once daily for six doses); treatment GF, gabapentin and firocoxib at previously stated doses and frequencies; or treatment C, grain only as a control. Treatments were administered in a randomized, crossover design, separated by 2 weeks. Subjective lameness score (SLS), inertial sensor vector sum (VS) calculations, peak vertical ground reaction force (PVGRF) measurements and vertical impulse (VI) calculations were determined immediately prior to each initial treatment dose and 2–4 hours after the final treatment dose for each treatment. Mean change in SLS, VS, PVGRF and VI for each treatment were compared among treatments. Results: The rank change in SLS of treatment GF was significantly greater than that of treatments C (p = 0.01) and G (p = 0.01) but not of treatment F (p = 0.08). No differences in VS (p = 0.4), PVGRF (p = 0.4) or VI (p = 0.1) were observed among treatments. Conclusions and clinical relevance: Gabapentin, as administered here, did not improve subjective or objective measures of lameness in horses with chronic thoracic limb musculoskeletal pain. Although subjective evaluation identified an improvement in lameness with treatment GF, it was not different from that observed with treatment F. Higher oral dosing and longer treatment regimens of gabapentin may be indicated for the treatment of chronic musculoskeletal pain in horses.
KW - equine chronic lameness
KW - firocoxib
KW - gabapentin
KW - pain management
UR - http://www.scopus.com/inward/record.url?scp=85078610670&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85078610670&partnerID=8YFLogxK
U2 - 10.1016/j.vaa.2019.11.003
DO - 10.1016/j.vaa.2019.11.003
M3 - Article
C2 - 31980368
AN - SCOPUS:85078610670
SN - 1467-2987
VL - 47
SP - 259
EP - 266
JO - Veterinary anaesthesia and analgesia
JF - Veterinary anaesthesia and analgesia
IS - 2
ER -